Anal HSIL clinical trials at University of California Health

1 research study open to eligible people

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
open to eligible people ages 21 years and up
This study is focused on treatment of anal high-grade squamous intraepithelial lesions (HSIL) in persons with HIV (PWH), with the ultimate goal of applying the approach toward prevention of anal cancer in this population
at UCSF

Our lead scientists for Anal HSIL research studies include Joel Palefsky.

Last updated: September 11, 2026

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial